RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aquestive Therapeutics Stock

Aquestive Therapeutics EBIT 2025

Aquestive Therapeutics EBIT

-43.66 M USD

Ticker

AQST

ISIN

US03843E1047

WKN

A2JQ4G

In 2025, Aquestive Therapeutics's EBIT was -43.66 M USD, a 59.17% increase from the -27.43 M USD EBIT recorded in the previous year.

The Aquestive Therapeutics EBIT history

YEAREBIT (undefined USD)
2030e-
2029e54.77
2028e8.72
2027e39.07
2026e-47.29
2025e-43.66
2024e-27.43
2023-15.1
2022-42.07
2021-34.68
2020-42.89
2019-52.66
2018-48.93
2017-0.11
2016-0.85
2006-12.2
2005-7.79
2004-3.52
2003-1.22

Aquestive Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aquestive Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aquestive Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aquestive Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aquestive Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aquestive Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aquestive Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aquestive Therapeutics’s growth potential.

Aquestive Therapeutics Revenue, EBIT and net profit per share

DateAquestive Therapeutics RevenueAquestive Therapeutics EBITAquestive Therapeutics Net Income
2030e404.91 M undefined0 undefined0 undefined
2029e282.44 M undefined54.77 M undefined71.61 M undefined
2028e191.1 M undefined8.72 M undefined25.11 M undefined
2027e140.22 M undefined39.07 M undefined-8.37 M undefined
2026e73.3 M undefined-47.29 M undefined-39.99 M undefined
2025e54.01 M undefined-43.66 M undefined-55.99 M undefined
2024e59.91 M undefined-27.43 M undefined-42.94 M undefined
202350.58 M undefined-15.1 M undefined-7.87 M undefined
202247.68 M undefined-42.07 M undefined-54.41 M undefined
202150.83 M undefined-34.68 M undefined-70.54 M undefined
202045.85 M undefined-42.89 M undefined-55.78 M undefined
201952.61 M undefined-52.66 M undefined-66.25 M undefined
201867.43 M undefined-48.93 M undefined-61.38 M undefined
201766.92 M undefined-110,000 undefined-11.42 M undefined
201651.79 M undefined-850,000 undefined-11.94 M undefined
20062.72 M undefined-12.2 M undefined-12.75 M undefined
20052.12 M undefined-7.79 M undefined-8.28 M undefined
20042.05 M undefined-3.52 M undefined-3.56 M undefined
200380,000 undefined-1.22 M undefined-1.22 M undefined

Aquestive Therapeutics stock margins

The Aquestive Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aquestive Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aquestive Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aquestive Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aquestive Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aquestive Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aquestive Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aquestive Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aquestive Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aquestive Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aquestive Therapeutics Margin History

Aquestive Therapeutics Gross marginAquestive Therapeutics Profit marginAquestive Therapeutics EBIT marginAquestive Therapeutics Profit margin
2030e58.82 %0 %0 %
2029e58.82 %19.39 %25.36 %
2028e58.82 %4.56 %13.14 %
2027e58.82 %27.86 %-5.97 %
2026e58.82 %-64.51 %-54.56 %
2025e58.82 %-80.84 %-103.66 %
2024e58.82 %-45.79 %-71.67 %
202358.82 %-29.86 %-15.56 %
202259.33 %-88.23 %-114.11 %
202170.51 %-68.23 %-138.78 %
202071.73 %-93.54 %-121.66 %
201961.3 %-100.1 %-125.93 %
201868.87 %-72.56 %-91.03 %
201770.38 %-0.16 %-17.07 %
201668.37 %-1.64 %-23.05 %
200640.07 %-448.53 %-468.75 %
200539.62 %-367.45 %-390.57 %
200432.2 %-171.71 %-173.66 %
200337.5 %-1,525 %-1,525 %

Aquestive Therapeutics Aktienanalyse

What does Aquestive Therapeutics do?

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Aquestive Therapeutics's EBIT

Aquestive Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Aquestive Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Aquestive Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Aquestive Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Aquestive Therapeutics stock

How much did Aquestive Therapeutics achieve in EBIT for the current year?

In the current year, Aquestive Therapeutics has achieved an EBIT of -43.66 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Aquestive Therapeutics.

How has the EBIT of Aquestive Therapeutics developed in recent years?

The EBIT of Aquestive Therapeutics has increased by 59.167% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Aquestive Therapeutics?

The EBIT of Aquestive Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 1/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/22/2025.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 1/22/2025.

What was the dividend of Aquestive Therapeutics in the year 2024?

In the year 2024, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aquestive Therapeutics

Our stock analysis for Aquestive Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aquestive Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.